NFL BIOSCIENCES SA (ALNFL.PA) Stock Price, Forecast & Analysis
Europe - Euronext Paris - EPA:ALNFL - FR0014003XT0 - Common Stock
ALNFL.PA Key Statistics, Chart & Performance
The current stock price of ALNFL.PA is 0.894 EUR. In the past month the price decreased by -14.02%. In the past year, price decreased by -49.67%.
ALNFL.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ARGX.BR | ARGENX SE | 74.67 | 49.19B | ||
| 1AE.DE | ARGENX SE | 72.95 | 48.06B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 20.07B | ||
| ABVX.PA | ABIVAX SA | N/A | 7.52B | ||
| 2X1.DE | ABIVAX SA | N/A | 7.89B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.78B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.78B | ||
| 5CV.DE | CUREVAC NV | 5.05 | 989.85M | ||
| NANO.PA | NANOBIOTIX | N/A | 859.20M | ||
| 6IV.DE | INVENTIVA SA | N/A | 713.45M | ||
| IVA.PA | INVENTIVA SA | N/A | 664.74M | ||
| PHIL.MI | PHILOGEN SPA | 20.18 | 672.52M |
Related stock screener links
About ALNFL.PA
Company Profile
NFL Biosciences SAS is a biotechnology company, which engages in the development of botanical drug candidates for the treatment of tobacco addiction and neurological diseases. The company is headquartered in Castelnau-Le-Lez, Occitanie and currently employs 4 full-time employees. The company went IPO on 2021-07-05. The firm's products help cure addictions through an approach based on botanical pharmaceutical agents. The company develops NFL-101, a patented, botanical drug candidate that aims at increasing the odds of quitting for smokers willing to quit. The firm applies scientific approach to other drug candidate with an initial focus targeting the growing addiction to cannabis.
Company Info
NFL BIOSCIENCES SA
199 rue Helene Boucher
Castelnau-le-Lez OCCITANIE FR
Employees: 4
Phone: 33411937667
NFL BIOSCIENCES SA / ALNFL.PA FAQ
Can you describe the business of NFL BIOSCIENCES SA?
NFL Biosciences SAS is a biotechnology company, which engages in the development of botanical drug candidates for the treatment of tobacco addiction and neurological diseases. The company is headquartered in Castelnau-Le-Lez, Occitanie and currently employs 4 full-time employees. The company went IPO on 2021-07-05. The firm's products help cure addictions through an approach based on botanical pharmaceutical agents. The company develops NFL-101, a patented, botanical drug candidate that aims at increasing the odds of quitting for smokers willing to quit. The firm applies scientific approach to other drug candidate with an initial focus targeting the growing addiction to cannabis.
Can you provide the latest stock price for NFL BIOSCIENCES SA?
The current stock price of ALNFL.PA is 0.894 EUR. The price decreased by -2.83% in the last trading session.
Does ALNFL stock pay dividends?
ALNFL.PA does not pay a dividend.
How is the ChartMill rating for NFL BIOSCIENCES SA?
ALNFL.PA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Would investing in NFL BIOSCIENCES SA be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ALNFL.PA.
What is the market capitalization of ALNFL stock?
NFL BIOSCIENCES SA (ALNFL.PA) has a market capitalization of 11.33M EUR. This makes ALNFL.PA a Nano Cap stock.
What is the ownership structure of NFL BIOSCIENCES SA (ALNFL.PA)?
You can find the ownership structure of NFL BIOSCIENCES SA (ALNFL.PA) on the Ownership tab.
ALNFL.PA Technical Analysis
ALNFL.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ALNFL.PA. While ALNFL.PA seems to be doing ok healthwise, there are quite some concerns on its profitability.
ALNFL.PA Financial Highlights
Over the last trailing twelve months ALNFL.PA reported a non-GAAP Earnings per Share(EPS) of -0.36. The EPS increased by 54.35% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -50.64% | ||
| ROE | -84.25% | ||
| Debt/Equity | 0.01 |
ALNFL.PA Forecast & Estimates
11 analysts have analysed ALNFL.PA and the average price target is 2.99 EUR. This implies a price increase of 234.67% is expected in the next year compared to the current price of 0.894.